Over the past decade, many TH mimetics with improved safety profiles, including TRβ-selective agonists and liver-selective TH analogs, have been developed as potential therapeutics for obesity, diabetes, and atherosclerosis8. Here, TH is linked to obesity due to melanocortin 4 receptor deficiency.